华丽家族: 华丽家族第七届监事会第二十七次会议决议公告

Group 1 - The company approved a cash increase of up to RMB 300 million to participate in the financing of Shanghai Haihe Pharmaceutical Research and Development Co., Ltd. [1][2] - The company plans to acquire no less than 5% and no more than 8.09% of the equity in Haihe Pharmaceutical after the financing is completed [1][2] - The company will subscribe to a maximum of 63.157895 million new shares at a price of RMB 4.75 per share [1][2] Group 2 - The company will sign a subscription agreement with Haihe Pharmaceutical and related parties, which requires approval from the shareholders' meeting [2] - The board of directors and management are authorized to sign supplementary agreements regarding specific subscription amounts and quantities after the subscription agreement takes effect [2]